
    
      This is a non-interventional, multi-centre, longitudinal observation with a defined
      population using a prospective cohort design to estimate the incidence of Pure Red Cell
      Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under
      treatment with Retacritâ„¢ (epoetin zeta) administered subcutaneously in patients with renal
      anaemia.
    
  